Core Points - The first batch of new registered companies in the Sci-Tech Innovation Board's growth tier, including Xian Yicai, Heyuan Bio, and Bibet, officially listed on October 28, marking a significant milestone for the board [1][4][7] - The listing increased the total number of companies in the growth tier to 35 and the total number of listed companies on the Sci-Tech Innovation Board to 592 [1] - The initial offering prices for the three companies were 8.62 CNY, 29.06 CNY, and 17.78 CNY per share, with significant price increases observed by midday trading on the listing day [1] Company Summaries - Xian Yicai's stock price rose to 26.74 CNY, reflecting a 210.21% increase from its offering price [1] - Heyuan Bio's stock reached 88.04 CNY, marking a 202.96% increase [1] - Bibet's stock price climbed to 34.44 CNY, showing a 93.7% increase [1] Regulatory and Policy Insights - The Vice Chairman of the China Securities Regulatory Commission (CSRC), Li Chao, emphasized the importance of utilizing reform policies to enhance development quality and investor returns [5][7] - Li noted that the establishment of the growth tier represents a solid step forward in capital markets supporting technological innovation and new productive forces [7] - The CSRC has implemented several significant policy measures, including the "1+6" reform framework, to facilitate the growth of high-tech enterprises [8] Government Support and Future Directions - Shanghai's Vice Mayor, Wu Wei, highlighted the city's commitment to building a world-class investment and financing ecosystem for "hard tech" companies [9][11] - Wu stated that the Sci-Tech Innovation Board has successfully nurtured a number of high-growth technology companies and has created replicable reform experiences [11] - The government aims to enhance the international competitiveness of Shanghai as a technology innovation hub [12] Market Dynamics and Future Outlook - The Shanghai Stock Exchange's Chairman, Qiu Yong, indicated that the board will continue to support "hard tech" companies with a focus on high standards and effective regulation [13][15] - The market is expected to see a continued influx of innovative companies as the regulatory environment becomes more accommodating [15][19] - The integration of technology, finance, and industry is anticipated to foster a virtuous cycle that supports sustainable economic growth [18][22]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) aims to deepen comprehensive reforms in the capital market to enhance its inclusiveness, adaptability, attractiveness, and competitiveness, thereby better serving the "14th Five-Year Plan" development goals and the construction of a financial power [1][7]. Group 1: Market Developments - The first batch of new registered companies in the Sci-Tech Innovation Board's growth layer was listed on October 28, marking a significant advancement in the board's reform and development [1]. - Three unprofitable companies, He Yuan Biological-U (688765.SH), Xi'an Yicai-U (688783.SH), and Bibete-U (688759.SH), collectively went public [1]. - As of now, the number of companies in the Sci-Tech Innovation Board's growth layer has reached 35, with a total of 592 listed companies on the board [6]. Group 2: Regulatory and Institutional Support - The CSRC has successfully implemented the "1+6" reform policy since June, which includes the introduction of professional institutional investors and pre-review systems [5]. - The Shanghai Municipal Government is actively collaborating with the CSRC to enhance the operational stability and functionality of the Sci-Tech Innovation Board [5]. - The Shanghai Stock Exchange (SSE) has completed preparations for rules, technology, and market readiness within four months following the reform policy's release [6]. Group 3: Future Plans and Strategic Focus - The CSRC plans to research and formulate strategic tasks and major initiatives for the capital market during the "14th Five-Year Plan" period, focusing on risk prevention, strong regulation, and promoting high-quality development [7]. - The SSE will focus on four key areas: maintaining the "hard technology" positioning, promoting development through reform, enhancing regulatory effectiveness, and prioritizing investor protection [8].

Core Insights - The China Securities Regulatory Commission (CSRC) is accelerating the planning for the capital market development in the next five-year period, focusing on risk prevention, strong regulation, and promoting high-quality development [1] - The CSRC aims to deepen comprehensive reforms in capital market investment and financing, enhancing the inclusiveness, adaptability, attractiveness, and competitiveness of China's capital market [1] Group 1: CSRC's Strategic Focus - The CSRC is committed to implementing a new round of capital market reform and opening up, with a focus on improving the coordination between investment and financing functions [1] - The CSRC emphasizes the importance of a robust regulatory framework to support high-quality development in the capital market [1] Group 2: Role of the Sci-Tech Innovation Board - The Sci-Tech Innovation Board (STAR Market) is increasingly demonstrating its role as a "testing ground" for reforms, leading to continuous improvements in the foundational systems of the entire market [2] - The CSRC encourages companies listed on the STAR Market to fully utilize reform policies to enhance corporate governance and improve development quality and investor returns [2] Group 3: New Listings on the STAR Market - The first three newly registered companies in the Sci-Tech Growth Layer officially listed on the STAR Market, just over four months after the CSRC announced the establishment of this layer [3] - Among the first three companies, two are high-tech firms in the biopharmaceutical sector, and one is in the semiconductor materials sector, all of which are currently unprofitable [3] - In 2023, the STAR Market has seen 11 companies listed, raising a total of 16.95 billion yuan in IPO financing, representing a 54% year-on-year increase [3]

Core Viewpoint - The role of the Sci-Tech Innovation Board as a "testing ground" for reforms is increasingly evident, supporting high-tech enterprises in fields such as integrated circuits and biomedicine, and accelerating the gathering of strong momentum for technological innovation [1] Group 1 - The first batch of newly registered companies on the Sci-Tech Innovation Board has been listed [1] - The China Securities Regulatory Commission (CSRC) Vice Chairman Li Chao emphasized the continuous improvement of the market's foundational systems [1] - The Sci-Tech Innovation Board is effectively supporting a number of high-tech enterprises [1]

Group 1 - The core message emphasizes the importance of enhancing the inclusiveness, adaptability, attractiveness, and competitiveness of China's capital market as outlined by the Chairman of the China Securities Regulatory Commission (CSRC), Wu Qing [1][2] - The CSRC plans to support emerging industries by implementing reforms in the Growth Enterprise Market (GEM) and establishing listing standards that cater to innovative enterprises in new sectors [1][2] - The introduction of the "Qualified Foreign Institutional Investor (QFII) Optimization Work Plan" aims to facilitate foreign investment by improving access management, operational efficiency, and expanding investment scope [1][2] Group 2 - The reform of the Sci-Tech Innovation Board (STAR Market) is accelerating, with the first batch of newly registered companies set to list, supported by measures such as the introduction of professional institutional investors [2] - Institutional reforms will focus on streamlining refinancing processes, expanding merger and acquisition support channels, and encouraging listed companies to enhance governance and return value to shareholders through dividends and buybacks [2] - The development of the Beijing Stock Exchange (BSE) will be promoted, along with the implementation of pioneering policies [2]

Group 1: Core Views - Three companies, Xian Yicai, Heyuan Bio, and Bibet, were listed on the Shanghai Stock Exchange on October 28, marking the first batch of companies in the newly established Sci-Tech Innovation Board Growth Tier [1] - The total number of companies in the Sci-Tech Innovation Board has reached 592, with 35 in the Growth Tier, reflecting the board's commitment to supporting hard technology enterprises [1] Group 2: Heyuan Bio - Heyuan Bio's new plant in Wuhan is set to produce 120 tons of raw liquid annually, with its recombinant human serum albumin injection approved for market entry, becoming the first of its kind in China [2][3] - The company aims to revolutionize the global albumin market with its "rice blood-making" technology, which eliminates reliance on plasma extraction [4][5] - Heyuan Bio has achieved a purity level of 99.9999% for its recombinant human serum albumin, significantly improving production efficiency and safety [6][7] Group 3: Bibet - Bibet, a biopharmaceutical company focused on oncology and metabolic diseases, was also listed on the Sci-Tech Innovation Board, emphasizing its commitment to source innovation [9][10] - The company is advancing its global first-in-class drug, BEBT-908, which targets difficult-to-treat lymphoma patients, and is in the process of accelerating its clinical trials [11][12] - Bibet has developed a comprehensive platform for siRNA drug development, with multiple projects in various clinical stages, showcasing its innovative capabilities [12][13] Group 4: Xian Yicai - Xian Yicai, a key player in the semiconductor materials sector, has become the first unprofitable company to be listed on the Sci-Tech Innovation Board, highlighting the board's support for hard technology firms [17][18] - The company has achieved significant production capacity in 12-inch silicon wafers, ranking first in China and sixth globally, and aims to enhance the competitiveness of China's semiconductor industry [19][20] - Xian Yicai plans to raise 4.9 billion yuan through its IPO to expand its production capacity and accelerate technological advancements, with a goal of reaching 1.2 million wafers per month by 2026 [23][24]

证监会主席吴清表示，纵深推进板块改革，增强多层次市场体系的包容性和覆盖面，10月28日科创板科 创成长层将迎来首批新注册企业上市，试点引入资深专业机构投资者、预先审阅等已经实施，改革效应 正加快显现，证监会还将启动实施深化创业板改革。除了关于深化创业板改革之外，吴清还在会上透露 将发布《关于加强资本市场中小投资者保护的若干意见》（以下简称《若干意见》），当晚，中小投资 者保护"23条"如期而至。 纵深推进创业板改革 10月27日，吴清重磅宣布将启动实施深化创业板改革。 吴清表示，纵深推进板块改革，增强多层次市场体系的包容性和覆盖面。将启动实施深化创业板改革， 设置更加契合新兴领域和未来产业创新创业企业特征的上市标准，为新产业、新业态、新技术企业提供 更加精准、包容的金融服务。 16年前，即2009年10月30日，创业板首批28只个股集体亮相，创业板开市。伴随着资本市场全面注册制 的推进，创业板也从核准制走向注册制。历经16年的发展，创业板也培育了不少龙头企业，包括宁德时 代、东方财富、新易盛、阳光电源等。 经统计，目前创业板市场共有1389只个股，合计总市值逼近18万亿元。 科创板改革效应正加快显现 北京商报 ...

10月27日，中国证监会主席吴清在2025金融街论坛上表示，纵深推进板块改革，增强多层次市场体系的 包容性和覆盖面。明天科创板科创成长层将迎来首批新注册企业上市，试点引入资深专业机构投资者、 预先审阅等已经实施，改革效应正加快显现。 中经记者 郭婧婷 北京报道 （编辑：罗辑 审核：夏欣 校对：颜京宁） ...

【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com （责任编辑：李悦 ） 证监会主席吴清10月27日在2025金融街论坛年会上表示，纵深推进板块改革，增强多层次市场体系的包 容性和覆盖面。明天科创板科创成长层将迎来首批新注册企业上市，试点引入资深专业机构投资者、预 先审阅等已经实施，改革效应正加快显现。 ...

Core Points - Three companies, Bibit (688759.SH), Heyuan Bio (688765.SH), and Xi'an Yicai (688783.SH), are set to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, marking the first batch of new listings since the launch of the Sci-Tech Growth Tier [1] - As of now, a total of 7.58 million investor accounts have opened trading permissions for the Sci-Tech Growth Tier, representing 126% of the active accounts among existing investors [1] - Following the release of the "1+6" policy reform for the Sci-Tech Board in June, 26 new companies have been accepted for listing, with 8 of them being unprofitable [1] - The first IPO application under the fifth set of listing standards, submitted by professional institutional investor Tianomaibo, was accepted on July 31 [1] - On September 26, the second IPO project under the restarted fifth set of listing standards, Anshi Bio, was accepted [1] - Companies such as Beixin Life, unprofitable company Moer Thread, and Angrui Micro have submitted registration on July 25, September 26, and October 15, respectively, under the fifth set of standards [1] - Unprofitable company Muxi Co. passed the listing committee review on October 24 [1]